erlotinib hydrochloride has been researched along with caffeine in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (caffeine) | Trials (caffeine) | Recent Studies (post-2010) (caffeine) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 25,501 | 2,393 | 6,825 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | caffeine (IC50) |
|---|---|---|---|
| Acetylcholinesterase | Homo sapiens (human) | 7.25 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berger, PB; Donzelli, M; Früh, M; Gillessen, S; Haschke, M; Joerger, M; Kloft, C; Krähenbühl, S; Parra-Guillen, ZP; Pfister, B; Winogradova, D | 1 |
1 trial(s) available for erlotinib hydrochloride and caffeine
| Article | Year |
|---|---|
Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment.
Topics: Aged; Antineoplastic Agents; Caffeine; Carcinoma, Non-Small-Cell Lung; Chromatography, Liquid; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP3A; Dried Blood Spot Testing; Drug Monitoring; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Midazolam; Middle Aged; Models, Biological; Pharmacogenetics; Pharmacogenomic Variants; Phenotype; Prospective Studies; Protein Kinase Inhibitors; Substrate Specificity; Tandem Mass Spectrometry; Treatment Outcome | 2017 |